It is expected to indirectly reduce the probability of peritoneal metastasis by developing a series of drugs targeting CXCL8 or CXCR1/2, or by improving the treatment effect of intraperitoneal chemotherapy on patients, slowing the deterioration of cancer after peritoneal metastasis. The gene discussed is CXCR1; the disease is cancer.